EBV-induced human B cell lymphomas in hu-PBL-SCID mice - PubMed (original) (raw)

Affiliations

PMID: 1325170

Review

EBV-induced human B cell lymphomas in hu-PBL-SCID mice

D E Mosier et al. AIDS Res Hum Retroviruses. 1992 May.

Abstract

Epstein-Barr virus (EBV) infection is associated with Burkitt's lymphoma (BL) in normal individuals and immunoblastic B cell lymphomas in immunosuppressed or HIV-infected individuals. SCID mice reconstituted with human peripheral blood leukocytes (hu-PBL-SCID) from EBV-seropositive donors also may develop spontaneous B cell lymphomas which histologically and phenotypically resemble post-transplant tumors, and are distinct from BL. These tumors always contain EBV DNA. We have noted three different reproducible outcomes depending upon the EBV-seropositive donor used for generation of hu-PBL-SCID mice: (i) no tumors appear; (ii) tumors appear in a fraction of hu-PBL-SCID mice with a 10-20 wk. latent period; or (iii) tumors appear in all hu-PBL-SCID mice within 6-10 wk. Southern blot analysis of late versus early tumors using a probe specific for the EBV terminal repeat sequences (BamNJ), which allows distinction between circular latent and linear replicating genomes, shows that late tumors do not involve active EBV replication but that early tumors do show replicating genomes. In addition, EBV genomes were monoclonal in late tumors but polyclonal in early tumors. These data suggest two mechanisms for EBV lymphomagenesis, slow outgrowth of rare latently-infected B cells, and more rapid transformation of uninfected bystander B cells by replicating virus. The latter process may be highly amenable to therapy in patients at risk for EBV-related lymphomas. In addition, prospective screening of EBV-seropositive transplant recipients in the hu-PBL-SCID model may predict the risk of post-transplant lymphoma development.

PubMed Disclaimer

Cited by

Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein-Barr Virus Lymphoproliferative Disorder.
Ahmed EH, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, Ozer HG, Schlotter S, Smith PL, Jeney F, Chan WK, Harrington BK, Weigel C, Brooks E, Klimaszewski HL, Oakes CC, Abebe T, Ibrahim ME, Alinari L, Behbehani GK, Shindiapina P, Caligiuri MA, Baiocchi RA. Ahmed EH, et al. Cancers (Basel). 2023 Jun 3;15(11):3046. doi: 10.3390/cancers15113046. Cancers (Basel). 2023. PMID: 37297008 Free PMC article.
Murine Models of Epstein-Barr Virus-Associated Lymphomagenesis.
Ahmed EH, Baiocchi RA. Ahmed EH, et al. ILAR J. 2016;57(1):55-62. doi: 10.1093/ilar/ilv074. ILAR J. 2016. PMID: 27034395 Free PMC article.
Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders.
Linnerbauer S, Behrends U, Adhikary D, Witter K, Bornkamm GW, Mautner J. Linnerbauer S, et al. PLoS Pathog. 2014 May 22;10(5):e1004068. doi: 10.1371/journal.ppat.1004068. eCollection 2014 May. PLoS Pathog. 2014. PMID: 24853673 Free PMC article.
Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.
Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, Plesa G, Zheng Z, Cotte J, Carpenito C, Wood T, Spratt SK, Ando D, Gregory P, Holmes MC, Perez EE, Riley JL, Carroll RG, June CH, Levine BL. Maier DA, et al. Hum Gene Ther. 2013 Mar;24(3):245-58. doi: 10.1089/hum.2012.172. Epub 2013 Mar 6. Hum Gene Ther. 2013. PMID: 23360514 Free PMC article.
Use of humanized severe combined immunodeficient mice for human vaccine development.
Koo GC, Hasan A, O'Reilly RJ. Koo GC, et al. Expert Rev Vaccines. 2009 Jan;8(1):113-20. doi: 10.1586/14760584.8.1.113. Expert Rev Vaccines. 2009. PMID: 19093778 Free PMC article. Review.

EBV-induced human B cell lymphomas in hu-PBL-SCID mice - PubMed (original) (raw)